SignalGeopolitics
Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued
Dupixent growth highlighted ahead of earnings, but valuation concerns temper the score.
Context
What happened: Regeneron Pharmaceuticals ($REGN) Q3 earnings are due October 30th, with another solid Dupixent contribution expected. The stock is rated Sell at $808.
Key numbers: Fair value ~$675, implying 16.4% downside risk. Dupixent patent expiration in 2031.
Why it matters: Dupixent growth is strong, but patent expiration and biosimilar risks cap long-term upside reflected in today's price. EYLEA HD gains are offset by legacy product declines, making slower franchise erosion critical for cash flow.
What changed
Regeneron Pharmaceuticals ($REGN) Q3 earnings are due October 30th, with another solid Dupixent contribution expected. The stock is rated Sell at $808.
Why it matters
Dupixent growth is strong, but patent expiration and biosimilar risks cap long-term upside reflected in today's price. EYLEA HD gains are offset by legacy product declines, making slower franchise erosion critical for cash flow.